Westminster, Colo., Jan. 13, 2026 — Cerapedics Inc. announced that the U.S. Food and Drug Administration (FDA) has approved expanded indications for use and labeling for PearlMatrix™ P-15 Peptide Enhanced Bone Graft, a Class III drug-device combination product designed to accelerate bone growth in lumbar spine fusion procedures. With this approval, PearlMatrix becomes the first and only proven bone growth accelerator authorized for all major lumbar interbody surgical approaches, significantly broadening its clinical applicability in patients with degenerative disc disease (DDD).
Science Significance
From a scientific standpoint, PearlMatrix represents a major advancement in orthobiologics and bone regeneration technology. The product leverages P-15 Peptide, a 15–amino acid sequence naturally found in Type-1 collagen, which plays a critical role in bone formation by attaching and activating osteogenic cells. By binding pharmaceutically manufactured P-15 Peptide to calcium phosphate particles, PearlMatrix creates a bioactive scaffold that accelerates new bone formation through natural cellular pathways. Clinical evidence from the pivotal ASPIRE study demonstrated statistically superior fusion speed and improved composite clinical success compared with local autograft, validating PearlMatrix’s mechanism-driven approach to accelerating lumbar fusion.
Regulatory Significance
Regulatorily, the expanded indication marks a significant milestone for Class III combination products, which face the highest level of FDA scrutiny. The original premarket approval (PMA) granted in June 2025 was supported by data from a prospective, randomized, controlled IDE study, reflecting rigorous adherence to Good Clinical Practice (GCP) and Quality System Regulation (QSR) standards. FDA approval of the supplemental application within three months highlights regulatory confidence in the strength and consistency of the clinical evidence. The expanded labeling now includes ALIF, PLIF, OLIF, LLIF, and TLIF procedures, as well as compatibility with PEEK, titanium alloy, and PEEK/titanium interbody fusion cages, reinforcing PearlMatrix’s regulatory robustness.
Business Significance
Advertisement
The approval significantly enhances Cerapedics’ commercial position within the lumbar fusion market, which accounts for approximately two-thirds of all spinal fusion procedures. By expanding on-label use across multiple surgical approaches, PearlMatrix gains access to a much broader surgeon and patient population. This milestone strengthens Cerapedics’ portfolio of FDA-approved drug-device products, reinforces its differentiation in the competitive bone graft market, and supports long-term revenue growth. The rapid regulatory turnaround also demonstrates the company’s ability to efficiently navigate complex regulatory pathways for high-risk medical technologies.
Patients’ Significance
For patients, the expanded approval translates into greater access to a proven technology that accelerates lumbar fusion. Traditional bone grafting approaches may be associated with slower fusion rates and additional surgical morbidity. PearlMatrix offers a clinically validated alternative that supports faster healing while maintaining a safety profile comparable to local autograft. Importantly, evidence from the ASPIRE trial demonstrated benefits across both general and high-risk patient populations, including individuals with Type 2 diabetes, elevated BMI, or nicotine use, groups that often face poorer surgical outcomes.
Policy Significance
At the policy level, the approval underscores the FDA’s commitment to science-driven evaluation of innovative medical devices and combination products. Accelerated access to technologies that improve surgical outcomes aligns with broader healthcare goals of reducing complications, shortening recovery times, and improving patient quality of life. The case also highlights the importance of robust post-market evidence generation and regulatory pathways that allow safe expansion of indications as new clinical data emerge. Such approvals help inform future standards of care and reimbursement discussions in spine surgery.
The FDA’s expanded approval of PearlMatrix™ P-15 Peptide Enhanced Bone Graft marks a pivotal advancement in lumbar spine fusion technology, combining strong clinical science, regulatory rigor, and meaningful patient benefit. By enabling use across all major lumbar interbody approaches, PearlMatrix sets a new benchmark for bone graft performance and regulatory success in the MedTech sector. As demand grows for solutions that improve fusion outcomes and accelerate recovery, this milestone reinforces the evolving role of drug-device combination products in modern orthopedic care.
Source: Cerapedics Inc press release
